文献速递免疫规划传染病防控与疫情报告

慢性蠕虫感染不损害小鼠对疟疾传播阻断疫苗Pfs230D1-EPA/Alhydrogel的免疫应答

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
PubMed 文献 · Vaccine · 2019-01-23

本研究利用慢性蠕虫(Hpb)感染小鼠模型,评估既往感染是否影响疟疾传播阻断疫苗Pfs230D1-EPA/Alhydrogel的活性。结果显示,感染鼠与未感染鼠在疫苗接种后第15、25、35天的Pfs230D1特异性IgG水平相似,疫苗激活B细胞绝对数相似,且通过减少蚊卵囊数评估的疫苗活性在两组间也相似。结论认为慢性蠕虫感染不损害该疫苗在小鼠中的效力。

要点

  • 慢性Hpb感染小鼠中,疫苗诱导的Pfs230D1特异性IgG水平与未感染鼠相似。
  • 疫苗激活的B细胞绝对数在感染与未感染免疫组间无差异。
  • 以蚊卵囊减少评估的疫苗活性在感染与未感染免疫鼠间相似。

核心结论

  • Pfs230D1-EPA/Alhydrogel的效力在小鼠中不被慢性蠕虫感染所损害。

研究设计与样本

  • 使用慢性蠕虫Heligmosomoides polygyrus bakeri(Hpb)感染的小鼠实验模型,比较Hpb感染鼠与未感染鼠接种Pfs230D1-EPA/Alhydrogel后的疫苗特异性免疫应答及疫苗活性。

主要发现

  • 慢性感染建立后,寄生虫抗原特异性IgG1、IgA和IgE抗体应答显著增加,同时全身IL-10、IL-5和IL-6水平升高。
  • 疫苗接种后第15、25和35天,Pfs230D1特异性IgG水平在感染与未感染小鼠间相似。
  • 疫苗诱导的Pfs230D1激活B细胞绝对数在免疫组间相似。
  • 通过减少恶性疟原虫感染蚊卵囊数评估的疫苗活性在Hpb感染免疫鼠与未感染免疫鼠间相似。

临床怎么用

  • 提示在疟疾与蠕虫共流行区,慢性蠕虫感染可能不削弱该候选传播阻断疫苗的免疫原性与效力,支持进一步临床评估。

局限性

  • 证据来自小鼠实验模型,不能直接外推至人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection. METHODS: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice. RESULTS: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice. CONCLUSION: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Coelho CH, Gazzinelli-Guimaraes PH, Howard J, et al. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice. Vaccine. 2019. PMID: 30685251. doi:10.1016/j.vaccine.2019.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。